Lianna Jean Marks, MD
Pediatric Hematology-Oncology · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Office
- 1
Offices
1 location
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Marks’s office at (650) 497-8000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
California Medical Board record
Licence A156744 · Current
Licensed to practise in California · since 2018 · expires 2028-07-31 · Indiana University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Pediatrics - Pediatric Hematology-Oncology
- American Board of Pediatrics - Pediatrics
Medicaid work
$6,320 in 2024
Medicaid paid $6,320 for 117 billed services this clinician did in 2024, up to 13 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 117 | $6,320 |
| 2024 | 117 | 1 | 13 | $6,320 |
| 2023 | 14 | 1 | 13 | $1,647 |
| 2022 | 96 | 1 | 13 | $5,953 |
| 2021 | 13 | 1 | 12 | $1,497 |
| 2020 | 31 | 1 | 13 | $3,126 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 14 | $1,647 |
2022
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 96 | $5,953 |
2021
| Return visit (30+ min) | 13 | $1,497 |
2020
| Return visit (30+ min) | 31 | $3,126 |
Money from drug and device companies
$4,773 in 2025
| 2025 | 1 | 6 | $3,750 | $4,773 |
| 2023 | 1 | 1 | None | $117 |
| 2022 | 1 | 1 | None | $73 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Pierre Fabre Pharmaceuticals | None | $4,773 | 6 payments
|
See all 6 published payments
| Pierre Fabre Pharmaceuticals | Honoraria · 2025-05-30 | None | $3,750 |
| Pierre Fabre Pharmaceuticals | Travel · 2025-05-30 | None | $584 |
| Pierre Fabre Pharmaceuticals | Meals · 2025-05-30 | None | $61 |
| Pierre Fabre Pharmaceuticals | Travel · 2025-05-30 | None | $226 |
| Pierre Fabre Pharmaceuticals | Meals · 2025-05-30 | None | $54 |
| Pierre Fabre Pharmaceuticals | Travel · 2025-05-30 | None | $98 |
See earlier years (2023, 2022)
2023: $117
| Seagen | None | $117 | 1 payment
|
2022: $73
| Seagen | None | $73 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Amgen Inc. · 2020 | Their institution | $54,263 |
| ABBVIE INC. · Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed Refractory Aggressive Mature B-Cell Neoplasms Receiving Subcutaneous (Sc) Injections of Epcoritamab · 2024 | Their institution | $43,456 |
| ABBVIE INC. · Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed Refractory Aggressive Mature B-Cell Neoplasms Receiving Subcutaneous (Sc) Injections of Epcoritamab · 2025 | Their institution | $33,024 |
| E.R. Squibb & Sons, L.L.C. · A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adult Participants With Recurrent Or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma · 2023 | Their institution | $24,006 |
| Amgen Inc. · B-Cell Maturation Antigen Expression in Pediatric Lymphoma · 2021 | Their institution | $18,088 |
| E.R. Squibb & Sons, L.L.C. · A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adult Participants With Recurrent Or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma · 2025 | Their institution | $11,334 |
| E.R. Squibb & Sons, L.L.C. · A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adult Participants With Recurrent Or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma · 2024 | Their institution | $6,528 |
| ABBVIE INC. · M20-429 - Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed Refractory Aggressive Mature B-Cell Neoplasms Receiving Subcutaneous (Sc) Injections of Epcoritamab · 2025 | Their institution | $3,200 |
| ABBVIE INC. · Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-Cell Neoplasms Receiving Subcutaneous (Sc) Injections of Epcoritamab · 2022 | This clinician | $1,708 |
| E.R. Squibb & Sons, L.L.C. · Phase I/Iia Pediatric Study - A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adult Participants With Recurrent Or Refractory Classical Hodgkin Lymphoma and Non-H · 2022 | Their institution | $316 |
| ABBVIE INC. · Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed & Refractory Aggressive Mature B-Cell Neoplasms Receiving Subcutaneous (Sc) Injections of Epcoritamab · 2023 | Their institution | $50 |
Professional record
- NPI
- 1982998126
- Licence
- CA A156744, NY 274578, PA MT199234California A156744: Current · expires 2028-07-31
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2080P0207X (2080P0207X); Pediatrics (208000000X)
- Mailing address
- 725 Welch Rd, Palo Alto, CA, 94304
- NPI first listed
- 2011-06-06
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.